Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pertuzumab biosimilar - EirGenix

Next Previous
Drug Profile

Pertuzumab biosimilar - EirGenix

Alternative Names: EG-1206A; Perjeta

Latest Information Update: 20 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator EirGenix
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Dimerisation inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Breast cancer

Most Recent Events

  • 12 Nov 2025 Pertuzumab biosimilar is still in phase I trials for Breast cancer in Germany
  • 12 Nov 2025 Sandoz in-licenses pertuzumab biosimilar from EirGenix, worldwide, excluding Taiwan, China, Macau, South Korea, Mongolia, Brunei, Cambodia, Indonesia, Laos, Myanmar, Philippines and Japan
  • 12 Nov 2025 EirGenix receives positive feedback from US FDA and EMA confirming that pertuzumab biosimilar qualifies for abbreviated development pathway, allowing for waiver of phase III trials

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top